lymphocytes, tumor-infiltrating

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Xiaoyi Jiang, Jian Wang, Xichen Zheng, Zhida Liu, Xinyu Zhang, Yuwei Li, Jonathan Wilhelm, Jun Cao, Gang Huang, Jinlan Zhang, Baran Sumer, Jayanthi Lea, Zhigang Lu, Jinming Gao, Min Luo

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e003960; DOI: 10.1136/jitc-2021-003960
Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells
David Noyes, Arup Bag, Saheed Oseni, Jon Semidey-Hurtado, Ling Cen, Amod A Sarnaik, Vernon K Sondak, Dennis Adeegbe

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004605; DOI: 10.1136/jitc-2022-004605
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
Pierre-Louis Bernard, Rebecca Delconte, Sonia Pastor, Vladimir Laletin, Cathy Costa Da Silva, Armelle Goubard, Emmanuelle Josselin, Rémy Castellano, Adrien Krug, Julien Vernerey, Raynier Devillier, Daniel Olive, Els Verhoeyen, Eric Vivier, Nicholas D Huntington, Jacques Nunes, Geoffrey Guittard

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004244; DOI: 10.1136/jitc-2021-004244
A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
Apple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Björn Önfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M Brea, Maria I Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004592; DOI: 10.1136/jitc-2022-004592
Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion
Byong-Sop Song, Ji Sun Moon, Jingwen Tian, Ho Yeop Lee, Byeong Chang Sim, Seok-Hwan Kim, Seul Gi Kang, Jung Tae Kim, Ha Thi Nga, Rui Benfeitas, Yeongmin Kim, Sanghee Park, Robert R. Wolfe, Hyuk Soo Eun, Minho Shong, Sunjae Lee, Il-Young Kim, Hyon-Seung Yi

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004337; DOI: 10.1136/jitc-2021-004337
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
Mark A J Gorris, Lieke L van der Woude, Leonie I Kroeze, Kalijn Bol, Kiek Verrijp, Avital L Amir, Jelena Meek, Johannes Textor, Carl G Figdor, I Jolanda M de Vries

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004329; DOI: 10.1136/jitc-2021-004329
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8⁺ T cell cytotoxicity over BEMPEG+RT
Annah S Rolig, Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L Redmond

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004218; DOI: 10.1136/jitc-2021-004218
Cancer stem-like cells evade CD8⁺CD103⁺ tumor-resident memory T (T_RM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model
Stéphanie Corgnac, Isabelle Damei, Gwendoline Gros, Aziza Caidi, Stéphane Terry, Salem Chouaib, Marc Deloger, Fathia Mami-Chouaib

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004527; DOI: 10.1136/jitc-2022-004527
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
Alexey Revenko, Larissa S Carnevalli, Charles Sinclair, Ben Johnson, Alison Peter, Molly Taylor, Lisa Hettrick, Melissa Chapman, Stephanie Klein, Anisha Solanki, Danielle Gattis, Andrew Watt, Adina M Hughes, Lukasz Magiera, Gozde Kar, Lucy Ireland, Deanna A Mele, Vasu Sah, Maneesh Singh, Josephine Walton, Maelle Mairesse, Matthew King, Mark Edbrooke, Paul Lyne, Simon T Barry, Stephen Fawell, Frederick W Goldberg, A Robert MacLeod

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e003892; DOI: 10.1136/jitc-2021-003892
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Eugene Y Chiang, Ira Mellman

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004711; DOI: 10.1136/jitc-2022-004711

Main menu

lymphocytes, tumor-infiltrating

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

lymphocytes, tumor-infiltrating

Pages